Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 08:05 ET | Source: VivoSim Labs, Inc.

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was...
May 07, 2025 04:26 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb...
March 28, 2025 13:58 ET | Source: Spherix Global Insights

Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth

EXTON, PA, March 28, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya...
March 28, 2025 07:20 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the...
March 09, 2023 08:51 ET | Source: The Insight Partners

8.4% CAGR for Capsule Endoscopy Market Size Worth $757.51 Million by 2028 – Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners

New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Capsule Endoscopy Market Size, Share, Growth and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By...
November 03, 2022 08:34 ET | Source: The Insight Partners

$11.72 Billion Growth for Enteral Feeding Formulas Market Size to Hit 6% CAGR by 2028 - The Insight Partners

New York, Nov. 03, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Enteral Feeding Formulas Market Size, Share and Forecast to 2028 – COVID-19 Impact and Global...
June 09, 2021 09:00 ET | Source: Qu Biologics, Inc.

Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
March 02, 2021 08:59 ET | Source: Emergen Research

Human Microbiome Therapeutics Market Size Worth USD 1,098.4 Million by 2027 | Rising Government Initiatives In Microbiome Research Projects And Increasing Drug-Related Side Effects Are Driving The Industry Growth, says Emergen Research

Vancouver, British Columbia, March 02, 2021 (GLOBE NEWSWIRE) -- The global Human Microbiome Therapeutics Market is forecasted to be worth USD 1,098.4 Million by 2027, according to a current analysis...
June 04, 2019 12:26 ET | Source: Trivedi Global, Inc.

Trivedi Global, Inc. Announces Research by Gopal Nayak on The Potential Benefits of Biofield Energy Treated Antineoplastic Chemotherapy Drug

Las Vegas, Nevada, US, June 04, 2019 (GLOBE NEWSWIRE) -- Gopal Nayak, today released research results on the beneficial impact of biofield energy treatment on improving physicochemical properties of...
December 03, 2018 07:00 ET | Source: Breathtec Biomedical Inc.

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease

VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...